Phase 2Recruiting
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients With Triple-class Refractory Multiple Myeloma
- Sponsor
- Karyopharm Therapeutics Inc (Industry)
- Enrolment
- 127 planned
- Conditions
- Multiple Myeloma, Refractory
- Interventions
- Selinexor; Dexamethasone; Bortezomib
- Ages
- adults, older adults
- Registry
- NCT04414475
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.
Primary outcomes
- Overall Response Rate (ORR)
History
Primary completion expected
Last registry update
Started
Registered